Home › Glioblastoma › Massachusetts › Boston
Glioblastoma clinical trials in Boston, MA
28 studies for Glioblastoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RecruitingPhase 2/3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
- Dana Farber Cancer Institute., Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
- Tufts Medical Center, Boston
Anti-GD2 ADC M3554 in Advanced Solid Tumors
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital - Neurology, Boston
- Dana-Farber Cancer Institute - Oncology Department, Boston
Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
- Dana-Farber Cancer Institute, Boston
Serial MRI Scans During Radiation Therapy
Recruiting
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
RecruitingPhase 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
RecruitingPhase 2
- Dana Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
RecruitingPhase 1
- Massachusetts General Hospital Cancer Center, Boston
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
G-CSF After Chemo-radiation in Patients With Glioblastoma
RecruitingPhase 2
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
CUE-102 in Recurrent Glioblastoma
RecruitingPhase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
RecruitingPhase 2
- Brigham and Women's Hospital, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RecruitingEarly phase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Implantable Microdevice In Primary Brain Tumors
RecruitingEarly phase 1
- Brigham and Women's Hospital, Boston
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
RecruitingObservational study
- Massachusetts General Hospital, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
RecruitingObservational study
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RecruitingObservational study
- Massachusetts General Hospital, Boston
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
RecruitingObservational study
- Massachusetts General Hospital, Boston
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
RecruitingObservational study
- Massachusetts General Hospital, Boston
Glioblastoma trials in other cities
- New York City, NY30 studies
- Houston, TX25 studies
- Los Angeles, CA23 studies
- Durham, NC20 studies
- San Francisco, CA17 studies
- Washington, DC15 studies
- Chicago, IL15 studies
- Rochester, MN15 studies
- Columbus, OH14 studies
- Miami, FL14 studies
- Jacksonville, FL13 studies
- Aurora, CO12 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.